Stock CRBP CORBUS PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
37.04 USD +3.93% Intraday chart for Corbus Pharmaceuticals Holdings, Inc. -1.85% +513.25%
Apr. 02 Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC CI
Mar. 13 Corbus Pharmaceuticals Files Mixed Shelf MT

Evolution of the average Target Price on Corbus Pharmaceuticals Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f2fd8ec745c.ijPuBW6m8GOmTPgPmwHV0NDjrdeq9-Mhw3oDvIHC8zI.zFTccSfKxij5Bagi4W6yhY-tlZb9ttMZjgJM0LCUtUP8atgzAdynCcMYrQ~94d3b9098dc06fe1873e705339a10c7a

Analyst Recommendations on Corbus Pharmaceuticals Holdings, Inc.

Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating MT
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $51 From $20, Maintains Outperform Rating MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $20 From $22, Maintains Outperform Rating MT
Oppenheimer Upgrades Corbus Pharmaceuticals to Outperform From Perform, $22 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
37.04 USD
Average target price
55 USD
Spread / Average Target
+48.49%
High Price Target
58 USD
Spread / Highest target
+56.59%
Low Price Target
52 USD
Spread / Lowest Target
+40.39%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Corbus Pharmaceuticals Holdings, Inc.

Oppenheimer
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRBP Stock
  4. Consensus Corbus Pharmaceuticals Holdings, Inc.